Citius Pharmaceuticals Inc (CTXR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.69M
Last updated: Nov 17, 2026 at 11:00 AM ET
Citius Pharmaceuticals Inc (CTXR) Earnings: Report Dates and Results
Citius Pharmaceuticals (CTXR) is expected to report earnings on Dec 21, 2026. In the quarter ended Jun 30, 2026, Citius Pharmaceuticals reported EPS of -$0.34, above the -$0.36 estimate. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CTXR has an expected report date of Dec 21, 2026.
Earnings History
Of the 32 quarters below that had an estimate, CTXR beat 11, missed 16 and matched 5. The widest gap in the table came in the quarter ended Sep 30, 2024, when EPS landed 286.67% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.34 | -$0.36 | -$0.36 - -$0.36 | +5.56% | Beat | N/A | 1 | 0 up, 0 down | Aug 14, 2026 | $1.49M |
| Mar 31, 2026 | -$0.95 | -$0.32 | -$0.32 - -$0.32 | -196.88% | Miss | N/A | 1 | 0 up, 0 down | May 15, 2026 | $1.67M |
| Dec 31, 2025 | -$0.38 | -$0.30 | -$0.30 - -$0.30 | -26.67% | Miss | N/A | 1 | 0 up, 0 down | Feb 13, 2026 | $3.94M |
| Sep 30, 2025 | -$0.11 | -$0.24 | -$0.24 - -$0.24 | +54.17% | Beat | N/A | 1 | 0 up, 1 down | Dec 25, 2025 | N/A |
| Jun 30, 2025 | -$0.80 | -$0.21 | -$0.21 - -$0.21 | -280.95% | Miss | N/A | 1 | 1 up, 0 down | Aug 12, 2025 | N/A |
| Mar 31, 2025 | -$1.27 | $0.11 | -$1.08 - $1.30 | N/A | N/A | N/A | 2 | 0 up, 0 down | May 14, 2025 | N/A |
| Dec 31, 2024 | -$1.30 | -$1.25 | N/A | -4.00% | Miss | N/A | 1 | 0 up, 0 down | Jan 3, 2025 | N/A |
| Sep 30, 2024 | -$5.80 | -$1.50 | N/A | -286.67% | Miss | N/A | 1 | 0 up, 0 down | Dec 27, 2024 | $155926 |
| Jun 30, 2024 | -$1.50 | -$1.12 | -$1.50 - -$1.00 | -33.93% | Miss | N/A | 2 | 0 up, 0 down | Aug 12, 2024 | N/A |
| Mar 31, 2024 | -$1.25 | -$1.50 | -$1.50 - -$1.50 | +16.67% | Beat | N/A | 1 | 0 up, 0 down | May 14, 2024 | N/A |
| Dec 31, 2023 | -$0.06 | $0.13 | $0.13 - $0.13 | -146.15% | Miss | N/A | 1 | 0 up, 0 down | Feb 14, 2024 | N/A |
| Sep 30, 2023 | -$1.75 | -$1.50 | N/A | -16.67% | Miss | N/A | 1 | 0 up, 0 down | Dec 29, 2023 | N/A |
| Jun 30, 2023 | -$1.50 | -$1.75 | -$1.75 - -$1.00 | +14.29% | Beat | N/A | 2 | 0 up, 0 down | Aug 14, 2023 | N/A |
| Mar 31, 2023 | -$1.75 | -$1.25 | -$1.25 - -$0.50 | -40.00% | Miss | N/A | 2 | 1 up, 0 down | May 12, 2023 | N/A |
| Dec 31, 2022 | -$0.02 | -$0.06 | N/A | +66.67% | Beat | N/A | N/A | 0 up, 0 down | Feb 10, 2023 | N/A |
| Sep 30, 2022 | -$1.25 | -$1.50 | N/A | +16.67% | Beat | N/A | 1 | 0 up, 0 down | Dec 22, 2022 | N/A |
| Jun 30, 2022 | -$1.50 | -$1.50 | -$1.75 - -$0.75 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Aug 11, 2022 | N/A |
| Mar 31, 2022 | -$1.25 | -$1.75 | -$2.00 - -$1.50 | +28.57% | Beat | N/A | 2 | 0 up, 0 down | May 12, 2022 | N/A |
| Dec 31, 2021 | -$1.50 | -$1.50 | -$1.50 - -$1.50 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Feb 10, 2022 | N/A |
| Sep 30, 2021 | -$0.02 | -$0.04 | -$0.05 - -$0.03 | +50.00% | Beat | N/A | 2 | 0 up, 0 down | Dec 15, 2021 | N/A |
| Jun 30, 2021 | -$1.25 | -$1.00 | N/A | -25.00% | Miss | N/A | 2 | N/A | Aug 12, 2021 | N/A |
| Mar 31, 2021 | -$1.00 | -$2.25 | -$2.25 - -$1.50 | +55.56% | Beat | N/A | 2 | N/A | May 13, 2021 | N/A |
| Dec 31, 2020 | -$0.15 | $0.16 | $0.16 - $0.16 | -193.75% | Miss | N/A | 1 | N/A | Feb 11, 2021 | N/A |
| Sep 30, 2020 | -$1.75 | -$2.50 | -$2.75 - -$2.50 | +30.00% | Beat | N/A | 2 | N/A | Dec 16, 2020 | N/A |
| Jun 30, 2020 | -$2.75 | -$2.75 | -$2.75 - -$2.50 | 0.00% | In line | N/A | 2 | N/A | Aug 14, 2020 | N/A |
| Mar 31, 2020 | -$3.25 | -$2.75 | -$2.75 - -$2.25 | -18.18% | Miss | N/A | 2 | N/A | May 14, 2020 | N/A |
| Dec 31, 2019 | -$3.75 | -$3.50 | -$3.50 - -$3.50 | -7.14% | Miss | N/A | 1 | N/A | Feb 13, 2020 | N/A |
| Sep 30, 2019 | -$0.16 | -$0.14 | -$0.14 - -$0.14 | -14.29% | Miss | N/A | 1 | N/A | Dec 16, 2019 | N/A |
| Jun 30, 2019 | -$5.00 | -$1.50 | N/A | -233.33% | Miss | N/A | N/A | N/A | Aug 14, 2019 | N/A |
| Mar 31, 2019 | -$5.00 | -$5.00 | -$5.00 - -$5.00 | 0.00% | In line | N/A | 1 | N/A | May 15, 2019 | N/A |
| Dec 31, 2018 | -$5.50 | -$5.25 | N/A | -4.76% | Miss | N/A | N/A | N/A | Feb 14, 2019 | N/A |
| Sep 30, 2018 | -$0.16 | -$0.16 | N/A | 0.00% | In line | N/A | N/A | N/A | Dec 11, 2018 | N/A |
| Jun 30, 2018 | -$4.75 | -$8.00 | -$8.00 - -$8.00 | +40.63% | Beat | N/A | 1 | N/A | Aug 14, 2018 | N/A |
| Mar 31, 2018 | -$0.44 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2018 | N/A |
| Dec 31, 2017 | -$0.38 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 20, 2018 | N/A |
| Sep 30, 2017 | -$0.43 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 13, 2017 | N/A |
| Jun 30, 2017 | -$0.49 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2017 | N/A |
| Mar 31, 2017 | -$0.55 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 15, 2017 | N/A |
| Dec 31, 2016 | -$11.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 14, 2017 | N/A |
| Sep 30, 2016 | -$13.28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 23, 2016 | N/A |
Annual EPS
EPS for the fiscal year ended Sep 30, 2026 was -$1.67, after -$3.48 the year before. It was -$12.56 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$1.67 | N/A |
| Sep 30, 2025 | -$3.48 | N/A |
| Sep 30, 2024 | -$8.61 | N/A |
| Sep 30, 2023 | -$5.02 | N/A |
| Sep 30, 2022 | -$5.50 | N/A |
| Sep 30, 2021 | -$2.42 | N/A |
| Sep 30, 2020 | -$11.50 | N/A |
| Sep 30, 2019 | -$15.66 | N/A |
| Sep 30, 2018 | -$5.73 | N/A |
| Sep 30, 2017 | -$12.56 | N/A |
Frequently Asked Questions About CTXR
When is Citius Pharmaceuticals's next earnings date?
Citius Pharmaceuticals's next earnings report is expected for Dec 21, 2026.
Did CTXR beat earnings estimates last quarter?
Yes. Citius Pharmaceuticals reported EPS of -$0.34 for the quarter ended Jun 30, 2026, above the -$0.36 estimate, a 5.56% surprise.
What EPS do analysts expect from CTXR next quarter?
The consensus EPS estimate for Citius Pharmaceuticals for the quarter ended Sep 30, 2026 is -$0.42 from 3 analysts.
How often does CTXR beat earnings estimates?
Citius Pharmaceuticals beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of -96.17%.
CTXR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors